Superpower peptides available for pre-order. Get first access.

Peptide science

What are thymosin peptides?

Thymosins share a name and a tissue of origin, not a structure. Learn how thymosin alpha-1, beta-4, and prothymosin alpha differ in biology and evidence.

Quick answer

Thymosin is a name, first used in 1966, for peptides from thymus extracts, not one molecule. Thymosin alpha-1 (28 amino acids) modulates immune signaling, thymosin beta-4 (43 amino acids) buffers cellular actin (a structural protein), and prothymosin alpha (111 amino acids) works in the nucleus. TB-500 is a 7-amino-acid beta-4 fragment. No thymosin is FDA-approved, though thymosin alpha-1 has been approved in other countries.

Published
April 18, 2026
Last updated
November 12, 2026

Key takeaways

  • What thymosins are: Thymosins are peptides first named in 19661 for a thymus extract. The name groups distinct molecules first found there, chiefly thymosin alpha-1, thymosin beta-4, and prothymosin alpha.
  • What each does: Thymosin alpha-1 adjusts immune signaling, thymosin beta-4 holds actin in reserve2, prothymosin alpha works in the cell nucleus, and TB-500 is a thymosin beta-4 fragment.
  • Approval: No thymosin is FDA-approved, though thymosin alpha-1 has been approved in other countries3 for hepatitis B and C.
  • US compounding: Under a draft HHS policy of October 30, 20264, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding TB-500 with a patient-specific prescription. Thymosin alpha-1 and full-length thymosin beta-4 are not among the peptides it covers.

Why the thymus gave thymosins their name

Thymosins are named for the thymus, where researchers looked for hormones that help the organ produce mature, self-tolerant T cells5.

Thymosin was first named in 1966, after a partial purification from thymus tissue6. Thymosin fraction 5, a calf-thymus preparation from the 1970s, held at least 40 mostly small polypeptides1. In several animal models and in people with immunodeficiency, fraction five restored immune defenses lost without thymic function7.

Because the thymus shrinks with age, a process called age-related thymic involution8, interest in thymic peptides lasted. Researchers went on to sort fraction five into its separate molecules.

Thymosin names a tissue source, not one structure

Thymosin is a name for peptides first found in one thymus extract, and its members are biochemically and functionally distinct9 molecules.

In T-cell tests, thymosin alpha-1, one component of fraction 5, was 10 to 1,000 times as active7 as fraction five itself. The beta thymosins, once thought to be thymic hormones, turned up in almost every cell2.

Thymulin, a separate thymic hormone outside the thymosin family, is a nine-amino-acid peptide made only by thymic epithelial cells10. Thymulin's activity depends on bound zinc11.

MoleculeSizeWhere it is foundMain role studied
Thymosin alpha-128 amino acids7Cut from the first 28 residues of prothymosin alpha12; free in the cytosol (cell fluid) of many tissuesImmune response modulation13
Thymosin beta-443 amino acids14Inside almost every cell, also in plasma and wound fluid2Binds actin monomers 1:1
TB-5007 amino acids, sequence Ac-LKKTETQ15Synthetic product, residues 17 to 23 of thymosin beta-4Copies the actin-binding stretch14 of thymosin beta-4
Prothymosin alpha111 amino acids16Cell nucleus17Proposed chromatin remodeling; physiological role still debated

Thymosin alpha-1 reached clinical use first.

Thymosin alpha-1 is the most clinically advanced thymosin

Thymosin alpha-1, also called thymalfasin or TA1 and sold abroad as Zadaxin, was the first thymosin in clinical use. By 2009, thymosin alpha-1 was approved in more than 35 countries3 for hepatitis B and C and as an immune stimulant.

Clinical thymosin alpha-1 is made by solid-phase peptide synthesis18. Thymosin alpha-1 appears to act through Toll-like receptors on dendritic cells19, triggering cytokine release.

A randomized controlled trial tested thymosin alpha-1 in 98 people with chronic hepatitis B infection. At 18 months, 40.6% of those given 26 weeks20 had cleared hepatitis B virus DNA and e antigen, versus 9.4% of controls. In a Phase 3 sepsis trial of 1,106 adults, 28-day mortality was 23.4% with thymosin alpha-1 and 24.1%21 with placebo, with no clear evidence of benefit.

Thymosin alpha-1's record lies in immune and infectious disease. Thymosin beta-4 drew researchers studying how cells move and repair tissue.

Thymosin beta-4 binds actin, and TB-500 is a fragment

Thymosin beta-4 is a 43-amino-acid peptide and the major actin-sequestering molecule14 in cells. Thymosin beta-4 holds actin building blocks in reserve until cells need filaments to move.

In mice with blocked coronary arteries, thymosin beta-4 improved early heart-muscle cell survival and function22.

Phase 3 trials have tested RGN-259, thymosin beta-4 eye drops, including for a corneal nerve disease. In an 18-person Phase 3 trial, 6 of 10 patients given the drops23 had fully closed corneal wounds at four weeks, versus 1 of 8 on placebo. The gap missed statistical significance, and the trial ended early for a business decision24. A second, 70-person Phase 3 trial finished in July 202625 and has not posted results.

TB-500 is a much smaller molecule, an acetylated copy of residues 17 to 2315 from thymosin beta-4. The heart and eye studies used full-length thymosin beta-4. Prothymosin alpha works elsewhere, inside the cell nucleus.

Prothymosin alpha is a nuclear protein tied to chromatin

Prothymosin alpha is a 111-amino-acid nuclear protein proposed to loosen chromatin (packaged DNA) through interaction with histone H117. The proposal draws on leukemia cell studies.

Prothymosin alpha and one of its fragments are candidate adjuvants for cancer immunotherapy26 (immune boosters added to vaccines), though clinical use remains a proposal. Each thymosin now holds a different regulatory status.

The regulatory status of each thymosin peptide

No thymosin is FDA-approved, and only TB-500 falls under HHS's draft compounding policy of October 30, 202627.

MoleculeDraft HHS compounding policy (October 30, 2026)Furthest human testing
Thymosin alpha-1Not covered; not among the 6 listed peptides4Phase 3 sepsis trial in 1,106 adults21
Thymosin beta-4 (full length)Not coveredCompleted Phase 3 eye-drop trials for dry eye in 601 adults28 and 700 adults29, without approval
TB-500Covered: HHS does not intend to take enforcement action4 against state-licensed pharmacies, federal facilities, or licensed physicians compounding injectable TB-500 with a patient-specific prescription, as a single active ingredientFDA has identified no human exposure data30; human orthopedic data lacking31
Prothymosin alphaNot coveredLaboratory research; proposed as a vaccine adjuvant26

The HHS policy is a non-binding draft that HHS may revisit27. Compounded drugs made under the policy are not FDA-approved.

Beyond the thymosins, peptide legality in the US varies by compound.

Where can I learn about peptides?

One family name covers several molecules with very different jobs, so it helps to know which thymosin a claim describes. Superpower’s peptide library covers thymosin alpha-1, thymosin beta-4, and TB-500 on separate pages. A team of health journalists and licensed clinicians writes and fact-checks every guide.

The science behind peptides explains how one thymus extract yielded an immune signal, an actin buffer, and a nuclear protein.

Important safety information

This page discusses multiple compounds in the thymosin family with varying regulatory statuses. No member of the thymosin family discussed here is FDA-approved for human use in the United States as of November 2026.

Thymosin alpha-1 (Zadaxin) holds approvals outside the United States but is not FDA-approved. It appears on FDA's list of bulk drug substances nominated but withdrawn from Category 2, and it is not covered by the draft HHS compounding policy of October 30, 2026. FDA has noted that compounded thymosin alpha-1 may pose a significant risk of immune reactions and raises impurity and characterization concerns.

Thymosin beta-4 has not received FDA approval for any indication; RGN-259, a thymosin beta-4 eye-drop formulation, has reached Phase 3 trials for neurotrophic keratopathy and dry eye without approval. Full-length thymosin beta-4 is not covered by the draft HHS compounding policy.

TB-500 is not FDA-approved and is not on the FDA's 503A bulks list. Under a non-binding draft HHS policy published October 30, 2026, HHS does not intend to take enforcement action against state-licensed pharmacies, federal facilities, or licensed physicians compounding injectable TB-500 as a single active ingredient with a patient-specific prescription. HHS may revisit that policy. Compounded drug products are not FDA-approved and are not evaluated by the FDA for safety, effectiveness, or quality. Prescription required.

Prothymosin alpha has no approved indication anywhere and remains a research compound.

No thymosin family compound discussed here has an approved US indication, so no US prescribing information or contraindication table exists. Talk with a licensed clinician before considering any of these compounds.

Populations of particular theoretical concern based on the compounds' proposed mechanisms include: active malignancy (immunomodulatory peptides may theoretically affect tumor biology); pregnancy, planning pregnancy, or breastfeeding (safety not established); concurrent immunosuppressive therapy following organ transplant (thymosin alpha-1 activation of adaptive immunity could theoretically provoke rejection); autoimmune conditions (immune activation is a theoretical concern); severe hypersensitivity to peptide formulations or to any excipient; pediatric populations (pediatric safety not established outside limited international pediatric hepatitis B programs for thymosin alpha-1).

Warnings (vary by compound): Thymosin alpha-1 international labeling lists injection site reactions, transient lymphocyte changes, and rare allergic reactions; its mechanism as a toll-like-receptor-mediated immunomodulator carries theoretical concerns in autoimmunity. Thymosin beta-4 and TB-500 have limited published human safety data, and FDA has identified no human exposure data for TB-500. Products sold online as TB-500 for research use are not subject to FDA oversight for identity, purity, sterility, or potency. Prothymosin alpha has no clinical safety database in humans.

Common side effects: Compound-specific. For thymosin alpha-1 (per international Zadaxin labeling): injection site reactions, transient discomfort, rare flu-like symptoms. For thymosin beta-4 and TB-500: not systematically characterized in published human trials. Reported anecdotal effects from unregulated use cannot substitute for controlled safety data.

Long-term data limitations: For TB-500 and prothymosin alpha, no completed U.S. Phase 2 efficacy trial exists. Long-term cancer risk, immune consequences, and safety in special populations have not been characterized for any thymosin family compound.

Compound references: PubChem CID 16130571 (thymosin alpha-1)32; PubChem CID 16132341 (thymosin beta-4)33. No FDA-approved prescribing information exists for any thymosin family compound in the United States.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to thymosin alpha-1, full-length thymosin beta-4, or prothymosin alpha. No thymosin peptide is FDA-approved for human use in the United States. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science